Summary
Commonly reported side effects of erlotinib include: infection, conjunctivitis, diarrhea, dyspnea, keratoconjunctivitis, nausea, pruritus, skin rash, stomatitis, anorexia, and xeroderma. Continue reading for a comprehensive list of adverse effects.
Applies to erlotinib: oral tablets.
Side effects include:
Adverse effects (≥20%): rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, vomiting.
For Healthcare Professionals
Applies to erlotinib: oral tablet.
Respiratory
Very common (10% or more): Dyspnea (41%), cough (33%)
Common (1% to 10%): Epistaxis, interstitial lung disease[Ref]
Dermatologic
Very common (10% or more): Rash (75%), alopecia (14%), pruritus (13%), dry skin (12%)
Common (1% to 10%): Acne, dermatitis acneiform, folliculitis, skin fissures, paronychia
Uncommon (0.1% to 1%): Hyperpigmentation, hirsutism, brittle/loose nails, eyebrow changes
Rare (less than 0.1%): Palmar plantar erythrodysesthesia syndrome, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)[Ref]
Gastrointestinal
Very common (10% or more): Diarrhea (54%), nausea (33%), vomiting (23%), stomatitis (22%), dyspepsia (17%), flatulence (13%), abdominal pain (11%)
Common (1% to 10%): GI bleeding
Uncommon (0.1% to 1%): GI perforations[Ref]
Hepatic
Common (1% to 10%): Liver function test abnormalities (including elevated ALT, AST, bilirubin)
Rare (less than 0.1%): Hepatic failure and hepatorenal syndrome (including fatalities)[Ref]
Immunologic
Very common (10% or more): Infections (24%)[Ref]
Ocular
Very common (10% or more): Keratoconjunctivitis sicca (12%), conjunctivitis (12%)
Common (1% to 10%): Keratitis
Uncommon (0.1% to 1%): Eyelash changes
Rare (less than 0.1%): Corneal ulcerations or perforations
Postmarketing reports: Uveitis[Ref]
Renal
Common (1% to 10%): Renal insufficiency
Uncommon (0.1% to 1%): Nephritis, proteinuria
Other
Very common (10% or more): Fatigue (73%), pyrexia (36%)[Ref]
Cardiovascular
Common (1% to 10%): Myocardial infarction/ischemia, cerebrovascular accident
Metabolic
Very common (10% or more): Anorexia (53%), weight decreased (39%)
Musculoskeletal
Very common (10% or more): Rigors (12%)
Postmarketing reports: Myopathy, including rhabdomyolysis, in combination with statin therapy
Nervous system
Very common (10% or more): Headache (15%), neuropathy (13%)
Psychiatric
Very common (10% or more): Depression (19%)